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Outcomes of a Rapid Deployment Aortic Valve Versus
Its Conventional Counterpart
A Propensity-Matched Analysis
Thorsten C.W. Wahlers, MD,* Martin Andreas, MD,† Parwis Rahmanian, MD,* Pascal Candolfi, PhD,‡
Barbora Zemanova, MSc,‡ Christophe Giot, MD,‡ Enrico Ferrari, MD,§ and Günther Laufer, MD†
Objective: The aim of this study was to compare outcomes after rapid-
deployment aortic valve replacement (RDAVR) and conventional aortic
valve replacement (AVR) from two studies.
Methods: Patients who underwent RDAVR (INTUITY valve) in the
prospective, 5-year, single-arm multicenter TRITON study, or con-
ventional AVR (Perimount Magna Ease valve) in the prospective
Perimount Magna Ease postmarket study, were propensity score
matched and compared for procedural, hemodynamic, safety, and
clinical outcomes.
Results:Matched RDAVR (n = 106) and conventional AVR (n = 106)
patients had similar baseline characteristics (mean ± SD age, 72.8 ± 7.6 vs
72.5 ± 7.4 years; male 59.4% vs 61.3%) and procedures (concomitant
procedures: 41.5% vs 50.9%). Mean ± SD aortic cross-clamp time was
significantly shorter in RDAVR than AVR patients (51.8 ± 20.9 vs
73.9 ± 33.2 minutes; P < 0.001), as was mean cardiopulmonary bypass
time (82.8 ± 34.2 vs 102.4 ± 41.7minutes;P < 0.001). At 1 year, RDAVR
patients showed significantly lower mean ± SD and peak aortic valve
gradients (9.0 ± 3.4 and 17.0 ± 6.2 mm Hg, respectively) than conven-
tional AVR patients (13.4 ± 5.5 and 24.2 ± 10.8 mm Hg, respectively;
all P < 0.001). Patient-prosthesis mismatch was significantly less
common with RDAVR than with AVR [overall: 16/66 (24.2%) vs
46/76 (60.5%); P = 0.007; severe: 2/66 (3.0%) vs 13/76 (17.1%)].
There were no significant differences between the RDAVR and AVR
groups regarding 30-day safety endpoints. Survival rates in the RDAVR
and conventional AVR groups were, respectively, 99.1% and 100.0% at
30 days, 97.1% and 95.1% at 1 year, and 93.3% and 94.1% at 3 years
(P = nonsignificant).
Conclusions: In this retrospective study with matched populations, the
RDAVR with the INTUITY valve system provided superior procedural
and hemodynamic outcomes than a standard bioprosthesis without
compromising safety.
Key Words: Aortic valve replacement, Aortic valve stenosis,
Rapid-deployment aortic valve replacement, Bioprosthetic valves.
(Innovations 2018;00:00–00)
Conventional aortic valve replacement (AVR) for aortic valvestenosis in patients older than 65 years is traditionally per-
formed with standard bioprostheses requiring several U-fashion
stitches or running sutures for the anchoring to the annulus.
The new bioprosthetic valves allowing rapid-deployment aortic
valve replacement (RDAVR) offer the potential for shorter aortic
cross-clamp time and cardiopulmonary bypass (CPB) time, with
shorter ventilation time and a similar survival rate when com-
pared with conventional AVR.1–8 Minimally invasive procedures
for AVR (such as the partial upper ministernotomy or the right
minithoracotomy) have been developed with the potential bene-
fits of shortened intensive care unit and hospital stay, shorter
ventilation time, and reduced blood loss.9 However, the major
drawback of these approaches is the longer cross-clamp time
and CPB time due to the more complex surgical procedures.9–12
Therefore, an RDAVR valve may be the ideal partner in mini-
mally invasive aortic valve surgery.
TheEdwards INTUITYvalve system (Edwards Lifesciences,
Irvine, CA USA) is a balloon-expandable, stented, bovine,
pericardial bioprosthesis based on the Edwards Perimount valve
system (Edwards Lifesciences, Irvine, CA USA).2–7,13,14 A
randomized controlled trial of minimally invasive RDAVR
with INTUITY valves recently reported shorter cross-clamp
time and improved hemodynamic function over 1 year versus
conventional full sternotomy AVR.6,7
The aim of this study is to compare procedural, hemody-
namic, safety, and midterm clinical outcomes (up to 3 years) of
two matched populations operated for AVR with the INTUITY
valve system and the standard Perimount Magna Ease valve.
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METHODS
Study Design
This is a retrospective study comparing the outcome of
patients operated for severe symptomatic aortic valve stenosis
with RDAVR using the INTUITY valve system and included
in the Surgical Treatment of Aortic Stenosis with an RDAVR
Surgical Aortic Valve (TRITON) study with patients treated
with conventional AVR using the Perimount Magna Ease valve
included in a prospective postapproval study. Propensity scoring
was used to generate two matched patient cohorts from these
two studies.
Data Collection and Patients
TRITON (Clinicaltrials.gov NCT01445171) was a pro-
spective, 5-year, single-arm, nonrandomized, multicenter trial
conducted in Europe to evaluate the Edwards INTUITY valve
(model 8300A or 8300AB), as previously described.3–5 Briefly,
recruited patients were male and female adults (aged ≥18 years)
undergoing planned aortic valve surgery for aortic stenosis with
or without aortic insufficiency, undertaken with or without con-
comitant procedures. Rapid-deployment aortic valve replacement
was performed either through a minimal invasive access (upper
ministernotomy or anterior right minithoracotomy) or through a
full sternotomy, according to the surgeon's preference. Primary
exclusion criteria included pure aortic insufficiency, concomitant
valve disease requiring repair with an annuloplasty ring or replace-
ment with prosthesis, left ventricular ejection fraction (LVEF) of
less than 25%, true bicuspid aortic valve (ie, Sievers type 0), and
myocardial infarction within 1 month or stroke within 6 months
before the scheduled RDAVR. Clinical and echocardiographic
follow-up data were collected at baseline, discharge, 3 months,
and 12months postoperatively and thereafter for 5 years. Hemo-
dynamic assessments were made according to guidelines,15 and
all hemodynamic data were reviewed by an independent echo-
cardiographic core laboratory (Columbia University Medical
Center, New York, NY USA).
The PerimountMagna Ease postapproval study (ClinicalTrials.
gov NCT01171625) was a prospective, single-arm, multicenter
international study designed to assess the midterm safety and
performance of the Perimount Magna Ease valve (model
3300TFX) in a postmarket, phase 4 setting. Based on the
Carpentier-Edwards Perimount valve system, the Perimount
Magna Ease valve is the conventional counterpart of the Edwards
INTUITY valve. The Perimount Magna Ease valve has shown
excellent clinical results and has been widely used.16 The
postmarketing study recruited male and female adults (aged
≥18 years) undergoing AVRwith or without concomitant proce-
dures. Patients were assessed at various time-points and signed
informed consents. Both studies obtained respective institu-
tional review board approvals before patient enrolment.3,16 Both
studies also used guidelines for reporting mortality and morbid-
ity after cardiac valve interventions.17
Statistical Analysis
This retrospective analysis included all patients in the
TRITON and Perimount Magna Ease postapproval studies who
completed 3 years of follow-up. The analysis used an “as treated”
approach, that is, excluding patients implanted with valves other
than the INTUITYor the Perimount Magna Ease.
Preoperative data were compared between the groups
using the independent samples t test for continuous variables
and Pearson χ2 test for discrete variables. Propensity scores,
calculated from baseline variables, were used to match patients
in two subgroups. A multivariable logistic regression model
including all 35 preoperative risk factors available within both
groups was applied (Supplementary Table S1, Supplemental Digital
Content 1, http://links.lww.com/INNOV/A177). The C-statistic was
0.864, indicating good discrimination. Patient-to-patient matching
was performed with the “Matching” library in the R Software (ver-
sion 4.8-3.4)18 using the nearest-neighbor matching without re-
placement algorithm, with a default caliper of 0.05 times the
standard deviation (SD) of the logit of the propensity scores.
The covariance balance was assessed by calculating stan-
dardized mean difference and performing paired t test and
McNemar test for continuous and discrete variables, respec-
tively. Further, pseudo R2 of the logistic regression model de-
creased from 0.329 on whole population to 0.067 on matched
population. This shows that risk factors do not explain the partic-
ipation probability after matching.
Baseline characteristics and postimplantation outcomes
common to both studies were compared between the matched
groups using the paired samples t test and McNemar tests for
continuous and discrete variables, respectively. The Wilcoxon
signed-rank test was used to compare mean valve sizes, after
matching. Performance outcomes compared were cross-clamp
and CPB times and 1-year hemodynamic variables, namely, LVEF,
mean and peak aortic gradients, effective orifice area (EOA) and
EOA indexed to patient body surface area (EOAi), and patient-
prosthesis mismatch (PPM; measured using transthoracic
echocardiography). Safety outcomes compared at 30 days after
implantation included all-cause mortality, bleeding, major bleed-
ing, endocarditis, valve explant, hemolysis, paravalvular leak,
pacemaker implantation, structural and nonstructural valve deteri-
oration, reoperation, thromboembolic event, valve thrombosis,
cardiac failure, and renal, respiratory, and sternal wound compli-
cations. Two-sided tests were used throughout, and a type I error
of 0.05 was considered significant. Kaplan-Meier survival curves
for the two groupswere compared using Cox regression, stratified
by matched pairs. All analyses were performed using the R soft-
ware (version 2.15.3).19 All data are expressed asmean ± standard
deviation (± SD) or as numbers and percentages (%).
RESULTS
Unmatched Group Characteristics
In the TRITON study, 287 of 295 patients enrolled in six
centers in Germany and Austria between January 2010 and
October 2012 received the Edwards INTUITY valve and com-
pleted a mean ± SD follow-up time of 2.7 ± 0.8 years. In the
Perimount Magna Ease postapproval study, 258 patients were
implanted with this valve between October 2007 and February
2013 and completed 3 years of follow-up. These populations
were the basis for this analysis.
Before matching, patients in the RDAVR group (n = 287)
were significantly older, more likely to be female, and generally
sicker than patients in the conventional AVR group (n = 258)
(Table 1). Rapid-deployment aortic valve replacement patients
had more severe heart failure and were more likely to have
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chronic renal failure, hypertension, arrhythmias (all P < 0.001),
and diabetes (P = 0.036). Rapid-deployment aortic valve re-
placement patients also showed more concomitant mitral
and tricuspid regurgitation than AVR patients (P < 0.001)
and were more likely to have a pacemaker already implanted
before surgery (P = 0.005).
Similar proportions of patients in the RDAVR and
conventional AVR groups underwent isolated AVR (55.1% and
TABLE 1. Preoperative Baseline Characteristics of Patients Who Underwent RDAVR in the TRITON Study and Conventional AVR in the
Perimount Magna Ease Postmarket Study, Before and After Propensity Score Matching
Before Matching After Matching
RDAVR (n = 287)*
Conventional AVR
(n = 258)* SMD P†
RDAVR
(n = 106)*
Conventional AVR
(n = 106)* SMD P‡
Age, y 75.3 ± 6.7 68.5 ± 8.8 0.866 <0.001 72.8 ± 7.6 72.5 ± 7.4 0.049 0.660
Male sex 146 (50.9) 167 (64.7) 0.283 0.001 63 (59.4) 65 (61.3) 0.039 0.877
NYHA III + IV 151/283 (53.4) 82/252 (32.6) 0.430 <0.001 49 (46.2) 48 (45.3) 0.019 1
Body surface area, m2 1.87 ± 0.19 1.96 ± 0.22 0.444 <0.001 1.91 ± 0.19 1.89 ± 0.20 0.073 0.614
Body mass index, kg/m2 28.0 ± 4.3 28.9 ± 5.6 0.190 0.028 28.0 ± 4.1 27.6 ± 4.3 0.092 0.542
Concomitant diseases
Coronary artery disease 139 (48.4) 106 (41.1) 0.148 0.102 50 (47.2) 55 (51.9) 0.094 0.583
Cardiomyopathy 7 (2.4) 5 (1.9) 0.034 0.916 6 (5.7) 4 (3.8) 0.089 0.752
Congestive heart failure 68 (23.7) 20 (7.8) 0.449 <0.001 9 (8.5) 9 (8.5) <0.001 1
Mitral regurgitation 176 (61.3) 62 (24) 0.814 <0.001 42 (39.6) 43 (40.6) 0.019 1
Tricuspid regurgitation 115 (40.1) 39 (15.1) 0.581 <0.001 30 (28.3) 28 (26.4) 0.042 0.871
Myocardial infarction 13 (4.5) 13 (5) 0.024 0.938 5 (4.7) 7 (6.6) 0.082 0.752
Arrhythmias, any 97/286 (33.9) 36 (14) 0.481 <0.001 22 (20.8) 24 (22.6) 0.046 0.864
RBBB 13/286 (4.5) 2 (0.8) 0.236 0.016 2 (1.9) 2 (1.9) <0.001 1
LBBB 16/286 (5.6) 9 (3.5) 0.101 0.334 3 (2.8) 4 (3.8) 0.053 1
Endocarditis 1 (0.3) 5 (1.9) 0.150 0.172 0 (0.0) 0 (0.0) NA NA
Dyslipidemia 157 (54.7) 163 (63.2) 0.173 0.055 63 (59.4) 64 (60.4) 0.019 1
History of rheumatic fever 0 (0) 5 (1.9) 0.199 0.055 0 (0.0) 3 (2.8) 0.241 0.248
Previous CABG 1 (0.3) 2 (0.8) 0.057 0.926 1 (0.9) 2 (1.9) 0.08 1
Previous PCI 23 (8) 12 (4.7) 0.138 0.154 4 (3.8) 6 (5.7) 0.089 0.752
Blood diatheses 6 (2.1) 1 (0.4) 0.154 0.167 2 (1.9) 1 (0.9) 0.08 1
Cancer 39 (13.6) 23 (8.9) 0.148 0.114 14 (13.2) 13 (12.3) 0.028 1
Chronic pulmonary disease 31 (10.8) 29 (11.2) 0.014 0.979 15 (14.2) 15 (14.2) <0.001 1
Diabetes 86 (30) 56 (21.7) 0.190 0.036 26 (24.5) 21 (19.8) 0.114 0.499
Liver disease 15 (5.2) 7 (2.7) 0.129 0.204 3 (2.8) 6 (5.7) 0.141 0.505
Chronic renal failure 46 (16) 5 (1.9) 0.508 <0.001 9 (8.5) 5 (4.7) 0.152 0.386
Alcohol or drug abuse 3 (1) 5 (1.9) 0.074 0.611 2 (1.9) 2 (1.9) <0.001 1
Atrial fibrillation/flutter 41/286 (14.3) 8 (3.1) 0.406 <0.001 9 (8.5) 7 (6.6) 0.071 0.789
TIA/CVA 10 (3.5) 15 (5.8) 0.111 0.274 3 (2.8) 2 (1.9) 0.062 1
Prior aortic valve surgery 0 (0) 2 (0.8) 0.125 0.433 0 (0.0) 0 (0.0) NA NA
AV block I 15/286 (5.2) 6 (2.3) 0.153 0.123 3 (2.8) 5 (4.7) 0.099 0.724
Pacemaker 13 (4.5) 1 (0.4) 0.270 0.005 0 (0.0) 1 (0.9) 0.138 1
Smoking, previous 54 (18.8) 96 (37.2) 0.418 <0.001 29 (27.4) 20 (18.9) 0.202 0.222
Smoking, current 16 (5.6) 16 (6.2) 0.027 0.898 6 (5.7) 10 (9.4) 0.143 0.453
Hypertension 249 (86.8) 171 (66.3) 0.498 <0.001 82 (77.4) 83 (78.3) 0.023 1
Surgical procedures 0.221 0.087 0.268 0.395
Isolated AVR 158 (55.1) 144 (55.8) 62 (58.5) 52 (49.1)
AVR + CABG 78 (27.2) 51 (19.8) 29 (27.4) 29 (27.4)
AVR + non-CABG 38 (13.2) 43 (16.7) 11 (10.4) 16 (15.1)
AVR + CABG + other 13 (4.5) 20 (7.8) 4 (3.8) 9 (8.5)
Variables are presented as mean ± SD or number and percentage (%).
*Denominator unless otherwise shown.
†Independent samples t test for continuous variables, Pearson χ2 test for categorical variables.
‡Paired samples t test for continuous variables, McNemar test for categorical variables.
AV block, atrioventricular block; AVR, aortic valve replacement; CABG, coronary artery bypass graft; CVA, cerebrovascular accident; LBBB, left bundle branch block; NA, not applicable;
NYHA, New York Heart Association; PCI, percutaneous coronary intervention; RBBB, right bundle branch block; RDAVR, rapid deployment AVR; SMD, standardized mean difference; TIA,
transient ischemic attack.
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55.8%, respectively), AVR plus coronary artery bypass grafting
(CABG) (27.2% and 19.8%), AVR plus a non-CABG procedure
(13.2% and 16.7%), or AVR plus CABG and at least one addi-
tional procedure (4.5% and 7.8%). The mean ± SD implanted
valve size was 23.1 ± 1.9 mm in the RDAVR group and
23.7 ± 2.2 mm in the conventional AVR group (P < 0.001).
Before matching, the mean ± SD propensity score was
0.72 ± 0.24 in the RDAVRgroup (n = 282; data missing for 5 pa-
tients) and 0.32 ± 0.25 in the conventional AVR group (n = 252;
data missing for 6 patients).
Matched Group Characteristics
Propensity score matching resulted in two similar groups,
each comprising 106 patients. The mean ± SD propensity scores
for the matched RDAVR and conventional AVR groups were
0.52 ± 0.23 and 0.52 ± 0.23, respectively.
The matched RDAVR and conventional AVR groups
showed similar baseline characteristics, as shown by standardized
mean differences of less than 0.1 for most variables (Table 1). In
addition, there is no significant difference in risk factors between
the two groups as tested by paired t test and McNemar test, re-
spectively. Similar proportions of matched RDAVR and conven-
tional AVR patients underwent isolated AVR (58.5% vs 49.1%,
respectively), AVR plus CABG (27.4% and 27.4%), AVR and a
non-CABG procedure (10.4% and 15.1%), or AVR plus CABG
and at least one additional procedure (3.8% and 8.5%). The mean
implanted valve sizewas 23.4 ± 1.8mm in the RDAVRgroup and
23.0 ± 2.3 mm in the conventional AVR group (P = 0.217). The
remaining results refer exclusively to the matched groups.
Procedural Outcomes
Mean ± SD aortic cross-clamp time was significantly
shorter in the matched RDAVR group (51.8 ± 20.9 minutes) than
in the AVR group (73.9 ± 33.2 minutes; P < 0.001), as was the
CPB time (82.8 ± 34.2 minutes vs 102.4 ± 41.7 minutes;
P < 0.001). Cross-clamp and CPB times were significantly
shorter in the RDAVR group versus the conventional AVR
cohorts also in the largest subgroups of patients undergoing
isolated AVR and AVR plus CABG (Table 2).
The distribution of the surgical approach for the INTUITY
arm after matching was full sternotomy 75.5% (80/106), mini-
upper sternotomy 19.8% (21/106), and right thoracotomy 4.7%
(5/106). Please note that surgical approach data are not available
for Magna Ease arm.
Valve Hemodynamic Performance at Follow-up
At 1-year follow-up, patients who underwent RDAVR
showed lower mean ± SD and peak valve gradients
(9.0 ± 3.4 mm Hg and 17.0 ± 6.2 mm Hg, respectively) than
those who underwent conventional AVR (13.4 ± 5.5 mm Hg
and 24.2 ± 10.8 mm Hg, respectively; P < 0.001 for both com-
parisons) (Table 3). Mean and peak gradients were significantly
lower in the RDAVR cohort for patient subgroups implanted
with 21-, 23-, and 25-mm valves. The same pattern of results
was seen in the 19 mm and 27 mm subgroups, although statis-
tical significance was not achieved in these small groups (Sup-
plementary Tables S2–S6, Supplemental Digital Content 2,
http://links.lww.com/INNOV/A190). Moderate-to-severe PPM
was significantly less common in the RDAVR group (overall
16/66; 24.2%) than the conventional AVR group (46/76;
60.5%; P = 0.007). Moderate PPM (EOAi, 0.65–0.85 cm2/m2)
was observed in 21.2% of the RDAVR group and 43.4% of
the conventional AVR groups, respectively, whereas severe
PPM (EOAi, <0.65 cm2/m2) occurred in 3.0% and 17.1% of the
cohorts, respectively (Table 3). Patient-prosthesis mismatch
was less common with RDAVR in each valve size subgroup
(Supplementary Tables S2–S6, Supplemental Digital Content
2, http://links.lww.com/INNOV/A190). The difference reached
TABLE 2. Intraoperative Procedural Times in the Matched
RDAVR and AVR Groups
Procedure Group
and Time Variable RDAVR
Conventional
AVR P
All patients n = 106 n = 106
AXC, min 51.8 ± 20.9 73.9 ± 33.2 <0.001
CPB, min 82.8 ± 34.2 102.4 ± 41.7 <0.001
Isolated AVR n = 62 n = 52
AXC, min 45 ± 18.7 64.6 ± 20.7 <0.001
CPB, min 71.4 ± 27.5 87.2 ± 24.0 0.001
AVR + CABG n = 29 n = 29
AXC, min 63.6 ± 20 97.1 ± 46.3 <0.001
CPB, min 102.3 ± 35 131.7 ± 56.6 0.022
AVR + non-CABG n = 11 n = 16
AXC, min 48.7 ± 13.8 60.6 ± 22.5 0.101
CPB, min 80.1 ± 33.3 97.1 ± 35.9 0.22
AVR + CABG + other n = 4 n = 9
AXC, min 80.2 ± 18.9 75.1 ± 19.5 0.67
CPB, min 126.2 ± 38.6 104.2 ± 26.3 0.354
Data are presented as mean ± SD or numbers and percentage (%).
P values from paired samples t test for analysis of all patients; independent samples t test
for subgroups.
AVR, aortic valve replacement; AXC, aortic cross-clamp; CABG, coronary artery bypass
grafting; CPB, cardiopulmonary bypass; RDAVR, rapid deployment AVR.
TABLE 3. Valve Hemodynamic Variables at 1 Year Postimplant
in the Matched RDAVR and Conventional AVR Groups
Variable RDAVR Conventional AVR P
Aortic gradient, mm Hg n = 84 n = 84
9.0 ± 3.4 13.4 ± 5.5 <0.001
Peak aortic gradient, mm Hg n = 84 n = 84
17.0 ± 6.2 24.2 ± 10.8 <0.001
EOA, cm n = 74 n = 76
1.7 ± 0.2 1.6 ± 0.4 0.120
EOAi, cm2/m2 n = 66 n = 76
0.9 ± 0.1 0.8 ± 0.2 0.070
Patient-prosthesis mismatch n = 66 n = 76 0.007
Moderate (EOAi 0.65–0.85 cm2/m2) 14 (21.2) 33 (43.4)
Severe (EOAi <0.65 cm2/m2) 2 (3.0) 13 (17.1)
LVEF, % n = 59 n = 82
65.1 ± 8.3 62.1 ± 7.5 0.146
Data are presented as mean ± SD or numbers and percentage (%).
P values from paired samples t test for continuous variables, McNemar for prosthesis‐
patient mismatch.
AVR, aortic valve replacement; EOA, effective orifice area; EOAi, index effective orifice
area; LVEF, left ventricular ejection fraction; RDAVR, rapid deployment AVR.
Wahlers et al Innovations • Volume 00, Number 00, Month/Month 2018
4 Copyright © 2018 by the International Society for Minimally Invasive Cardiothoracic Surgery
statistical significance in the largest 23-mm valve subgroup:
moderate PPM occurred in 3/27 (11.1%) of these RDAVR pa-
tients (no severe episodes), whereas in the conventional AVR
subgroup there were 13 patients (46.4%) with moderate PPM
and 5 patients (17.9%) with severe PPM (overall P < 0.001).
Left ventricular ejection fraction did not differ significantly be-
tween the groups.
Clinical Safety Outcomes
The matched RDAVR and conventional AVR groups did not
differ significantly with respect to 30-day safety endpoints (Table 4)
or 3-year Kaplan-Meier survival curves (Fig. 1). This was the case
for patients in each subgroup categorized by the procedure type, that
is, isolated AVR, AVR plus CABG, AVR plus non-CABG, and
AVR plus CABG and another procedure (Supplementary Tables
S7–S10, Supplemental Digital Content 3, http://links.lww.com/
INNOV/A191). It should be noted that RDAVR group did have nu-
merically higher numbers of patients with major bleeding, major pa-
ravalvular leak, permanent pacemaker implantations, and acute
kidney failure (Table 4). Estimated survival rates in the RDAVR
and conventional AVR groups were, respectively, 99.1% vs
100.0% at 30 days, 97.1% vs 95.1% at 1 year, 93.3% vs 95.1%,
at 2 years, and 93.3% vs 94.1% at 3 years (Fig. 1).
DISCUSSION
This propensity-matched analysis showed that patients
who underwent RDAVR with the INTUITY valve system had
significantly shorter aortic cross-clamp and CPB times, lower
mean and peak aortic valve gradients, lower risk of moderate
or severe PPM, and similar safety and survival rates over 3 years,
as compared with patients who underwent conventional AVR
with standard Perimount valves. Although this was a retrospective
analysis, propensity score matching rendered two well-matched
cohorts of patients that did not differ significantly according to
a battery of preoperative variables andwhichwere therefore suit-
able for comparison. Propensity score matching is a powerful
statistical tool to strengthen causal inferences drawn from ret-
rospective studies and to ensure that only similar patients are
selected. It is increasingly used and accepted in the literature,
most notably for medical devices where randomized controlled
FIGURE 1. Kaplan-Meier survival curves for the matched cohorts after rapid-deployment aortic valve replacement (RDAVR; Edwards
INTUITY) and conventional aortic valve replacement (AVR; Perimount Magna Ease).
TABLE 4. Safety Outcomes in the Matched RDAVR and
Conventional AVR Groups at 30 Days After Implantation
Outcome
RDAVR
(n = 106)
Conventional AVR
(n = 106) P
Mortality 1 (0.9) 0 (0) 1
Bleeding 13 (12.3) 4 (3.8) 0.052
Major bleeding 11 (10.4) 3 (2.8) 0.061
Endocarditis 0 (0) 0 (0) NA
Valve explant 2 (1.9)* 1 (0.9) 1
Paravalvular leak (degree 1–2) 2 (1.9) 0 (0) 0.48
Major paravalvular leak (degree 3–4) 2 (1.9) 0 (0) 0.48
Reoperation† 2 (1.9) 1 (0.9) 1
Structural valve deterioration 0 (0) 0 (0) NA
Nonstructural valve deterioration 0 (0) 0 (0) NA
Permanent pacemaker implantation 7 (6.6) 4 (3.8) 0.546
Thromboembolic events 4 (3.8) 3 (2.8) 1
Valve thrombosis 0 (0) 0 (0) NA
Heart failure 1 (0.9) 1 (0.9) 1
Acute kidney failure 7 (6.6) 1 (0.9) 0.077
Respiratory failure/pneumonia 5 (4.7) 5 (4.7) 1
Sternal wound complications 4 (3.8) 5 (4.7) 1
Data are presented as numbers and percentage (%).
P values from McNemar test.
*See Kocher et al3 for details.
†The reasons for reoperation were specified as moderate paravalvular leak (n = 1) and
bleeding-hemolysis (n = 1) in the RDAVRgroup and “other, not specified” in the AVR group
(n = 1).
AVR, aortic valve replacement; NA, not applicable; RDAVR, rapid deployment AVR.
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trials are more challenging to perform and real-world evidence
can be more powerful.20,21 These results add to a growing body
of evidence suggesting that RDAVR offers procedural benefits
and improved hemodynamics compared with conventional aortic
bioprostheses. Experts have recently recommended that sutureless
and rapid deployment valves should be considered as the prosthesis
of choice for isolated aortic valve procedures in patientswith comor-
bidities, in the elderly, and in certain other circumstances such as
complex concomitant procedures requiring longer surgical time.22
The aortic cross clamp time and CPB time are predictors
of mortality, morbidity, and length of hospital stay in patients un-
dergoing AVR.10–12 The procedural times for conventional AVR
in the present analysis are consistent with reported ranges in the
available literature.2,23–25 In this analysis, RDAVR was associ-
ated with significantly reduced cross-clamp and CPB times over-
all and, in particular, in the subgroups who underwent AVR only
or AVR plus CABG. A systematic review of 11 studies using
three different valve products recently concluded that RDAVR
was invariably associated with shorter aortic cross-clamp times
than conventional AVR (30–56 minutes vs 49–88 minutes).1
Most of these studies were cohort studies, but the findings
were confirmed by the prospective, randomized, multicenter
CADENCE-MIS study. CADENCE-MIS compared minimal
invasive RDAVR (using the INTUITY aortic valve system
without concomitant procedures; n = 46) versus AVR via full
sternotomy using a conventional stented valve of the investi-
gator's preference (n = 48).6,7 Minimal invasive RDAVR was
associated with significantly reduced cross-clamp times compared
withconventionalAVR(41.3±20.3minutesvs54.0±20.3minutes;
P < 0.001), although CPB time was not significantly shortened.
Supporting results were also provided by a single-center, parallel
cohort study that compared RDAVR with the INTUITY valve
(n = 116) versus conventional AVRwith Perimount Magna Ease
(n = 132).2 Patients were neither randomized nor matched in this
study, and the mean ± SD valve size was significantly higher in
the conventionalAVRgroup thanRDAVRgroup (23.2±2.0mmvs
22.5 ± 2.2 mm; P = 0.007). Minimal invasive procedures were
significantly more common among patients implanted with the
RDAVR valve than conventional valve (59% vs 39%; P < 0.001)
and, although cross-clamp times were similar between the groups
overall, RDAVR was associated with reduced cross-clamp time,
perfusion, and procedural times versus conventional AVR in pa-
tients who underwent full sternotomy.2 Recently, a propensity-
matched, single-center study (n = 41 pairs) also confirmed that
RDAVR was associated with significantly shorter cross-clamp
time (71 ± 33 minutes vs 106 ± 42 minutes; P < 0.01) and
CPB times (95 ± 42minutes vs 134 ± 47minutes;P < 0.01) than
conventional AVR, when both types of prosthesis were implanted
through a full sternotomy.8 In this analysis, RDAVRwas also as-
sociated with significantly lower rates of moderate and severe
PPM at 1 year versus conventional AVR, together with lower
mean and peak transvalvular gradients.
Patient-prosthesis mismatch occurs when the EOA of the
bioprosthesis is too small compared with the patient's body
size, causing a high transvalvular gradient and lower long-term
survival.26–28 Our findings are consistent with previously reported
studies. In the CADENCE-MIS, minimal invasive RDAVR pa-
tients also had significantly lower peak gradients after 1 year,
with a trend toward lower mean gradients, and a significantly
greater EOA compared with the control group.7 In the afore-
mentioned parallel cohort study,2 the subgroup analysis of the
most common valve sizes (21 mm and 23 mm; implanted in
64% of patients) also showed significantly lower mean postop-
erative transvalvular gradients in the RDAVR group than the
conventional AVR group. Moreover, the aforementioned multi-
product systematic review reported benefits of RDAVR on post-
operative bleeding, blood transfusion requirements, ventilation
time, and renal injury.1 Another recent propensity-matched,
single-center study (n = 41 pairs) showed significant benefits of
RDAVR over conventional AVR on mean ± SD ventilation time
(17 ± 25 hours vs 63 ± 131 hours; P < 0.01), intensive care unit
stay (51 ± 45 hours vs 108 ± 157 hours; P = 0.03), and new onset
of postoperative atrial fibrillation/flutter (8% vs 20%; P = 0.02).8
In the present analysis, we found no significant differ-
ences between the matched RDAVR and conventional AVR
groups with respect to safety endpoints assessed at 30 days
postimplant, including new permanent pacemaker implantation.
The 3-year Kaplan-Meier survival rates were also good and
similar between the cohorts. These data support previous evi-
dence that mortality rates with RDAVR are similar to those with
conventional AVR.1,2,7,8 Further real-world evidence regarding
longer-term outcomes after RDAVR is awaited from ongoing
registry studies.29,30
There are some limitations with this study; this was a retro-
spective analysis of data over a 6-year period from two separate
studies with differing protocols and available datasets. Studies
of this type are inherently subject to a significant risk of bias, in-
cluding allocation bias associated with surgeon preference and
classification bias arising from data collection and recording.
Therefore, the propensity score matching was used to create com-
parable cohorts from these studies. Although the matched cohorts
did not differ significantly according to available data, the poten-
tial for additional, untested confounding variables to introduce
bias cannot be fully excluded. The analysis was also limited to
the outcomes variables for which data were available, at com-
mon timepoints, from both studies. Pertinent data that may have
been informative, but which were unavailable from at least one
study, included the surgical approach and the left ventricular
mass regression. This study was specifically designed to com-
pare cohorts implanted with the INTUITY and the Perimount
Magna Ease valve and therefore rates of conversion from the
INTUITY valve to conventional valve (eg, because of severe pa-
ravalvular leak) were not analyzed. However, there were no sig-
nificant differences in paravalvular leak rates between the two
cohorts. Finally, our analysis was limited to 3-year follow-up
and a longer follow-up might be necessary to unmask potential
survival benefit with the RDAVR valve.
In conclusion, in this multicentric, retrospective analysis
of matched populations, the RDAVR using the INTUITY valve
system provided superior procedural and hemodynamic out-
comes compared with the conventional AVRwith the Perimount
Magna Ease valve, without compromising safety.
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CLINICAL PERSPECTIVE
This propensity-matched analysis compared patients who underwent implantation of the Edwards Lifesciences rapid-deployment
INTUITY valve (RDAVR) during the prospective multicenter TRITON study, to those who underwent conventional AVR with
a PerimountMagna Ease valve in a prospective postmarket study. One hundred six propensity-matched patients in each group were
compared. They had similar baseline characteristics. The mean cross-clamp timewas significantly shorter in the RDAVR group as
was mean cardiopulmonary bypass time. At 1 year, RDAVR patients had significantly lower mean and peak aortic valve gradients.
There was no difference in 30-day safety endpoints and no difference in survival. The authors concluded that RDAVR with the
INTUITY valve system provided superior procedural and hemodynamic outcomes, without compromising safety.
This is an interesting propensity-matched retrospective analysis that adds further data to support the use of rapid deployment valves.
However, this study has significant limitations. It was a retrospective analysis and was not a randomized trial. Most importantly, the
relatively small number of matched patients in each group left it underpowered to detect what might have been important dif-
ferences. With these limitations in mind, shorter operative times and better valve hemodynamics were shown to be advantages
of rapid-deployment valves.
Innovations • Volume 00, Number 00, Month/Month 2018 RDAVR Superior to Conventional AVR
Copyright © 2018 by the International Society for Minimally Invasive Cardiothoracic Surgery 7
